Uncategorized
iCo Therapeutics reports $0.02 loss per share in Q2 financial results
Second-quarter results released by iCo Therapeutics included a total comprehensive loss of $1,617,040, or a $0.02 loss per share, compared with a total comprehensive loss of $2,886,831, or a $0.05 loss per share, for Q2 of last year.These financial results represent a decrease of $1,269,791 in comprehensive loss, according to a company press release.